New drug cocktail aims to stop leukemia return after transplant

This study tests whether adding two drugs (SHR2554 and azacitidine) to standard chemotherapy before a stem cell transplant can lower the chance of leukemia coming back. It includes 160 people aged 15-60 with high-risk or relapsed acute leukemia or myelodysplastic syndromes. Participants are randomly assigned to get the new drug combo or standard chemo, then all receive a stem cell transplant. The main goal is to see if the new approach reduces relapse within two years.